Triple therapy with or without radiation for EGFR-mutant lung cancer with brain metastases
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This study tests a new combination of drugs (sacituzumab tirumotecan plus a third-generation EGFR inhibitor) with or without radiation therapy for advanced lung cancer that has spread to the brain after prior EGFR inhibitor treatment. The goal is to see if this combination can better control the cancer and improve outcomes for patients with brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with advanced (stage IV) non-small cell lung cancer, not a squamous or small cell type.
- Your tumor tests positive for an EGFR mutation (either exon 19 deletion or exon 21 L858R).
- You have taken an EGFR inhibitor (like erlotinib, gefitinib, or osimertinib) and your cancer continued to grow.
- You have brain metastases that can be seen on an MRI.
- You are generally in good physical shape (able to do light activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
This study tests a new combination treatment (SCTB41 plus docetaxel) for people with advanced non-small cell lung cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
This trial studies a new drug called sacituzumab tirumotecan combined with brain radiation for people with EGFR-positive lung cancer that has spread to the brain and has grown despite targeted therapy. The goal is to see if this combination can better control the brain tumors.
This trial tests a combination of two drugs, sacituzumab tirumotecan and bevacizumab, for people with EGFR-mutant lung cancer that has spread to the brain. It aims to see if this combination can shrink tumors and improve outcomes after standard EGFR inhibitor treatment has stopped working.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.